Purdue Licenses Flu Vaccine Tech to PaxVax
The Purdue Research Foundation last week said that it has licensed intellectual property related to an adenovirus-based vaccine for bird flu to San Diego-based vaccine maker PaxVax.
Developed by researchers at Purdue University’s School of Veterinary Medicine and the Centers for Diseases Control and Prevention, the IP involves genetic modification of the adenovirus so it is unable to replicate.
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.
UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.
Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.
In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.